These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 11127251)

  • 21. [Topical treatment of persistent cutaneous leishmaniasis with paromomycin].
    Flaig MJ; Rupec J; Ruzicka T; Rupec RA
    Hautarzt; 2007 Aug; 58(8):689-90, 692. PubMed ID: 17676349
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of visceral leishmaniasis in Kenya by aminosidine alone or combined with sodium stibogluconate.
    Chunge CN; Owate J; Pamba HO; Donno L
    Trans R Soc Trop Med Hyg; 1990; 84(2):221-5. PubMed ID: 2167522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of canine leishmaniosis with aminosidine at an optimized dosage regimen: a pilot open clinical trial.
    Athanasiou LV; Saridomichelakis MN; Kontos VI; Spanakos G; Rallis TS
    Vet Parasitol; 2013 Feb; 192(1-3):91-7. PubMed ID: 23140991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hearing loss associated with paromomycin treatment in a patient with visceral leishmaniasis].
    Furones Araujo D; Gallego Fernández C; Asensi-Diez R
    Farm Hosp; 2017 May; 41(3):433-434. PubMed ID: 28478760
    [No Abstract]   [Full Text] [Related]  

  • 25. A new breakthrough in treatment of visceral leishmaniasis in children.
    Hassan M; Baat DB; Hassan K
    J Pak Med Assoc; 1995 Jun; 45(6):155-7. PubMed ID: 7474290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (= paromomycin)-antimonial combinations, a pilot study in Bihar, India.
    Thakur CP; Olliaro P; Gothoskar S; Bhowmick S; Choudhury BK; Prasad S; Kumar M; Verma BB
    Trans R Soc Trop Med Hyg; 1992; 86(6):615-6. PubMed ID: 1337634
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A prospective randomized, comparative, open-label trial of the safety and efficacy of paromomycin (aminosidine) plus sodium stibogluconate versus sodium stibogluconate alone for the treatment of visceral leishmaniasis.
    Thakur CP; Kanyok TP; Pandey AK; Sinha GP; Zaniewski AE; Houlihan HH; Olliaro P
    Trans R Soc Trop Med Hyg; 2000; 94(4):429-31. PubMed ID: 11127250
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of paromomycin sulphate topical ointment as effective therapeutic agent in cutaneous leishmaniasis.
    Sahibzada NJ; Tareen AK; Khursheed T; Darr N
    J Pak Med Assoc; 1996 Mar; 46(3):53-5. PubMed ID: 8991348
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clarification of comments on trial of aminosidine in visceral leishmaniasis.
    Olliaro P; Jha TK
    BMJ; 1998 Oct; 317(7167):1250. PubMed ID: 9794877
    [No Abstract]   [Full Text] [Related]  

  • 30. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug watch.
    Indian Pediatr; 1998 Jul; 35(7):696. PubMed ID: 10216689
    [No Abstract]   [Full Text] [Related]  

  • 32. A randomized, placebo-controlled trial of a two-week regimen of aminosidine (paromomycin) ointment for treatment of cutaneous leishmaniasis in Iran.
    Asilian A; Jalayer T; Whitworth JA; Ghasemi RL; Nilforooshzadeh M; Olliaro P
    Am J Trop Med Hyg; 1995 Dec; 53(6):648-51. PubMed ID: 8561269
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of visceral leishmaniasis in 2010: direction from Bihar State, India.
    Murray HW
    Future Microbiol; 2010 Sep; 5(9):1301-3. PubMed ID: 20860475
    [No Abstract]   [Full Text] [Related]  

  • 34. Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis.
    Hepburn NC; Tidman MJ; Hunter JA
    Trans R Soc Trop Med Hyg; 1994; 88(6):700-3. PubMed ID: 7886779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sodium stibogluconate and paromomycin for treating visceral leishmaniasis under routine conditions in eastern Sudan.
    Atia AM; Mumina A; Tayler-Smith K; Boulle P; Alcoba G; Elhag MS; Alnour M; Shah S; Chappuis F; van Griensven J; Zachariah R
    Trop Med Int Health; 2015 Dec; 20(12):1674-84. PubMed ID: 26427033
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India.
    Olliaro P; Sundar S
    Trop Med Int Health; 2009 Jan; 14(1):88-92. PubMed ID: 19121150
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy of aminosidine administered alone or in combination with meglumine antimoniate for the treatment of experimental visceral leishmaniasis caused by Leishmania infantum.
    Gangneux JP; Sulahian A; Garin YJ; Derouin F
    J Antimicrob Chemother; 1997 Aug; 40(2):287-9. PubMed ID: 9301998
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tetany in kala azar patients treated with paromomycin.
    Thakur CP
    Indian J Med Res; 2008 May; 127(5):489-93. PubMed ID: 18653914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis.
    Afzal I; Sarwar HS; Sohail MF; Varikuti S; Jahan S; Akhtar S; Yasinzai M; Satoskar AR; Shahnaz G
    Nanomedicine (Lond); 2019 Feb; 14(4):387-406. PubMed ID: 30688557
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Challenges in the management of visceral leishmaniasis.
    Sundar S; Kumar A
    Indian Pediatr; 2005 Jun; 42(6):523-6. PubMed ID: 15995268
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.